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1. Introduction 
B-cell chronic lymphocytic leukemia (CLL) is a mature B-cell neoplasm. Affecting mainly the 
elderly, CLL represents the most common hematological malignancy in Western countries, 
and 6-7% of non Hodgkin’s lymphomas.  
The disease course is heterogenous. Clinical staging systems (i.e. Rai and Binet) are used for 
estimating the tumor burden and prognosis and for making therapeutic decisions in 
individual patients. However, the evolution, even in the early stages, remains highly 
variable with at least 50% of cases showing early or late progression. Since the large majority 
of newly diagnosed cases present with early or intermediate stage, it is important to assess 
the risk profile within this group. 
Several biological variables have been proposed for the prognostic stratification of early stage 
CLL, including chromosomal abnormalities [as assessed by karyotyping or fluorescent in situ 
hybridization (FISH)], expression of CD38, the proportion of ZAP-70-positive cells, somatic 
hypermutation of the variable part of the B-cell receptor gene (IGVH) and VH 3-21 usage. In 
addition, acquisition of particular chromosomal aberrations could be relevant, i.e. a 17p 
deletion appearing during the disease course confers resistance to alkylating agents and 
purine analogs, underscoring the need for defining the genetic patterns of disease evolution. 
Here, chromosomal aberrations in CLL will be reviewed. First, the different techniques to 
detect abnormalities will be described. Second, the CLL-associated (cyto)genetic 
abnormalities and their relevance for clinical practice will be discussed, with a focus on the 
role of these aberrations in disease onset, progression, and on their prognostic significance. 
2. Cytogenetic techniques 
Numerous studies have shown that the presence, number, and type of chromosomal 
aberrations represent an independent predictor of prognosis in CLL (Döhner et al, 2000; 
Juliusson et al, 1990; Mayr et al, 2006; Van Den Neste et al, 2007). Therefore, cytogenetic 
analysis is now routinely performed in this disease. Different techniques are available to 
detect chromosomal abnormalities. Conventional cytogenetic analysis (CCA) can be 
performed, but is hampered by the poor mitotic index of CLL lymphocytes in vitro. 
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Although several mitogens have been used to overcome this problem, alternative 
approaches allowing analysis of nondividing cells are available, i.e. interphase FISH is 
widely used and has become the standard technique. In addition multiplex ligation-
dependent probe amplification (MLPA) (Coll-Mulet et al, 2008; Fabris et al, 2011) and more 
recently analysis by means of different array-platforms (Gunn et al, 2008; Hagenkord et al, 
2010) have been investigated in research and routine setting.  
2.1 Conventional cytogenetic analysis 
CCA or chromosome banding analysis (CBA) examines the patient’s chromosomes in a 
sample of cells. Counting the number of chromosomes and evaluating their structural 
aberrations (banding patterns) results in the construction of a karyogram and karyotype. 
The resolution is determined by the number of bands seen in a haploid set of chromosomes 
(300-850 bands, each band contains approximately 5-10 megabase of DNA) (Shaffer et al, 
2009). The work-flow of the technical procedure is shown in Fig 1. Peripheral blood is the 
preferred tissue for CCA in CLL, but bone marrow, lymph node, spleen or effusions can be 
analyzed as well.  
Since CLL is a malignancy of mature B-cells, these cells are often arrested at the G0G1 phase of 
the cell cycle and do not divide spontaneously. They accumulate primarily as a result of lack of 
apoptosis, rather than by accelerated cell division (Chiorazzi, 2007). As a consequence, CLL 
lymphocytes have a poor mitotic index in vitro. Therefore longer culture duration has been 
introduced, i.e. 72 hours instead of 24-48 hours, and several stimulating agents have been 
added to the culture medium. Mitogens and agents such as 12-O-tetradecanoylphorbol-13-
acetate (TPA), the lectine phyotohemagglutinin (PHA), lipopolysaccharide (LPS) and 
pokeweed mitogen (PWM), the cytokine interleukin-2 (IL-2) and Epstein-Barr virus, have been 
used to improve the yield of aberrant metaphases. However, abnormal karyotypes were 
revealed in only 40–50% of cases (Juliusson et al, 1990). These low abnormality detection rates 
can be attributed to a lack of aberrant metaphases, i.e. proliferation disadvantage of the 
aberrant B-cell clone, and to the presence of cryptic deletions escaping the low resolution of 
CCA. Recently, improved culture methods have been introduced, i.e. CD40 ligand (CD40L)-
induced cell cycle stimulation, and the immunostimulatory CpG oligonucleotide (DSP30) 
(Dicker et al, 2006; Haferlach et al, 2007; Mayr et al, 2006; Put et al, 2009a; Struski et al, 2009).  
2.1.1 TPA 
Before the introduction of DSP30, the phorbol ester TPA was considered to be the 
stimulating agent of choice to improve the mitotic index of CLL cells. TPA stimulates slowly 
proliferating immature B-cells by activating protein kinase C. This results in 
phosphorylation of downstream proteins, maturation of these cells towards a plasmacytoid 
phenotype and inhibition of apoptosis (Barragan et al, 2002). However, the induction of cells 
in G2 and metaphase is weak (2-10%) (Carlsson et al, 1988; Stephenson et al, 1991).  
In addition, TPA has been shown to induce the IL-2 receptor and CLL colony formation. The 
addition of the cytokine IL-2 to TPA stimulated CLL cell cultures was reported to directly 
stimulate CLL proliferation, even in absence of T-lymphocytes (Touw and Lowenberg, 
1985). Although the latter findings provide evidence for the addition of IL-2 to TPA cultures, 
it is not mandatory for successful CCA (Put et al, 2009a; Struski et al, 2009). 
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2.1.2 CD40-ligand (CD40L) 
As metaphase induction by TPA is weak and aberration detection is inferior compared with 
FISH, efforts were made to improve culture methods. In contrast to the environment of 
lymph node proliferation centers, in vitro cultures do not protect the lymphocytes from 
apoptotic and cytotoxic triggers. The addition of CD40 was able to induce an antiapoptotic 
profile in CLL cells (Hallaert et al, 2008) and therefore it could improve the generation of 
metaphases. CD40 is an antigen expressed on the surface of normal and malignant B-cells 
and induces cell cycle progression after activation by its ligand (Buhmann et al, 2002). 
CD40L-induced cell cycle stimulation resulted in a threefold increase in generation of 
metaphases compared with stimulation with B-cell mitogens such as TPA, LPS and PWM. In 
addition, the success rate of CCA and aberration detection rate were higher in the CD40L 
cultures (93% vs. 78% and 89% vs. 22%, respectively) (Buhmann et al, 2002). However, this 
technique is labor-intensive and expensive, and therefore not applicable for routine analysis. 
2.1.3 DSP30 
At the present time, the best CCA results in CLL are obtained with the addition of CpG 
oligodinucleotides (ODN) and IL-2 to the culture medium. ODN containing a CpG motif, 
such as DSP30, stimulate cells of the immune system via the Toll-like receptor 9 (TLR9). In 
humans, the only cell types known to express TLR9 are B-cells and plasmacytoid dendritic 
cells (Hornung et al., 2002). It has been established that CpG stimulates a broad spectrum of 
B-cell malignancies, i.e. CLL (Jahrsdorfer et al, 2005). CpG induces proliferation in normal B-
cells; however, proliferation is weaker and followed by increased apoptosis in CLL cells 
(Jahrsdorfer et al, 2005). The lower proliferative response to CpG-ODN in CLL cells 
compared with normal B-cells can be overcome by addition of IL-2. Indeed, compared with 
normal B-cells, CpG causes a stronger induction of the IL-2 receptor ǂ chain (CD25) in CLL, 
resulting in higher numbers of IL-2 receptors with a stronger affinity. Costimulation with 
CpG and IL-2 might alter IL-2 signaling in CLL cells in addition to increase cytokine 
production and surface molecule expression (Decker et al., 2000a).  
The use of CpG/IL-2 improves proliferation capacity of CLL cells, and therefore it enables 
karyotyping in more cases (79-98%). Moreover, the technique yields detection rates of 
aberrations comparable with interphase FISH (81–83%) (Dicker et al., 2006; Haferlach et al., 
2007). Other groups confirmed an improvement of the aberration detection rate in CpG/IL-2 
(i.e. an increase of 9-13% of cases with aberrations) compared with TPA stimulated cultures 
(Put et al, 2009a; Struski et al, 2009). Moreover, the detection of translocations and del(13q) in 
particular, has been found to be superior after CpG/IL-2 stimulation compared with TPA 
(Put et al, 2009a). 
The influence of CpG/IL-2 on quality of banding and metaphase generation is not clear (Put 
et al, 2009a; Struski et al, 2009). 
Another question to address is whether abnormalities found after CpG/IL-2 stimulation might 
be related to activation-induced cytidine deaminase (AID). CpG stimulation of CLL and 
normal B-cells induces expression of AID, an enzyme that is linked to the development of 
genetic abnormalities (Capolunghi et al., 2008). However, culturing B-cells of healthy blood 
donors with CpG/IL-2 did not induce clonal abnormalities, thus validating CpG/IL-2 as a tool 
for the cytogenetic analysis of CLL (Dicker et al, 2006; Put et al, 2009a; Wu et al, 2008).  
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In conclusion, CpG/IL-2 should be preferred for routine CCA of CLL. However, as neither 
conventional cytogenetics nor CLL-specific FISH can detect all aberrations, both techniques 
should be complementarily applied.  
2.2 FISH 
FISH uses labeled DNA probes directed to selected targets and has a higher resolution than 
standard cytogenetics (approximately 40 Kb - 1 Mb, depending on the size of the FISH-
probes vs. 10 Mb, respectively). Moreover, it can be used on metaphases and on nondividing 
cells. Sample types that may be used for FISH include in most cases peripheral blood or 
bone marrow, but also lymph node, spleen or effusions. Either uncultured fresh or frozen 
cells, cultured fixed cells, or paraffin-embedded tissue sections can be investigated.  
The procedure is summarized in Fig 2. Interphase FISH yields high rates of detection of 
abnormalities, i.e. 80% (Döhner et al, 2000). However, this technique provides only partial 
information confined to the chromosomal loci examined, whereas CCA gives an overview of 
all microscopically visible aberrations.  
Although FISH is a very sensitive technique, one should consider certain shortcomings. As 
already mentioned, a limited number of probes is applied. For this reason FISH can 
underestimate genomic complexity. False-positive and false-negative interpretations occur in 
5% of FISH assays (Smoley et al, 2010). Wrong results may be due to i.e. inadequate cut-offs, co-
hybridization or poor hybridization of probes, background signals, difficulties in visualizing 
probe signals in different planes of the nucleus, inadequate probes [in case of microdeletions or 
microduplications, i.e. ATM or miR-15a/16-1, in which the probe may be too large or not 
covering the deletion]. Lack of proliferation of the aberrant clone can occur when FISH is 
performed on cultured material. Furthermore, complex and cryptic translocations may generate 
special patterns of FISH signals that do not match the normal, expected signal pattern. 
In clinical practice, FISH is performed for the regions 17p13 (TP53), 11q13 (ATM), chromosome 
12 and 13q14 (RB1 and  miR15.a/16.1). The panel can be extended with probes for the regions 
6q21 and 14q32 (IGH). Of interest, particular aberrations detected by FISH (discussed in 
section 3.1), e.g. loss of 17p13, were identified as major prognostic markers in CLL.  
Hence abnormalities detected by FISH may guide patient monitoring and therapeutic 
decisions. Moreover FISH analysis is recommended for pretreatment evaluation and before 
subsequent, second- or third-line treatment (Hallek et al, 2008). 
2.3 MLPA 
Since FISH is a quite laborious, time-consuming and expensive technique, MLPA has been 
developed as an alternative tool. This technique relies on the comparative quantitation of 
specifically bound probes that are amplified by polymerase chain reaction (PCR) with 
universal primers. The latter allows simultaneous processing of multiple samples and has 
proven to be accurate and reliable for identifying deletions, duplications, and amplifications 
(Coll-Mulet et al, 2008). The procedure is summarized in Fig 3. (Schouten et al, 2002) and an 
example of MLPA results is shown in Fig 4. In a study comparing FISH and MLPA on 100 
samples of untreated early stage (Binet A) CLL patients, a high degree of concordance 
between both techniques was observed (95%). Seven aberrations were not detected by 
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Fig. 4. Example of MLPA analysis performed in two cases of CLL (A and B).  
Arrows indicate the unbalanced regions: (1) gain of 8q24 and (2) loss of 13q14 in case A, 
and (3) loss of 6q25 and (4) loss of exon 5 of TP53 on 17p13 in case B. (Courtesy of M. 
Jarosova) 
MLPA, probably due to the low percentage of leukemic cells (<30%) carrying the aberration 
(Fabris et al, 2011). The sensitivity may even be lower if no B-cell pre-enrichment is 
performed (i.e. aberrations not detected when the percentage of leukemic cells <50%). 
Moreover MLPA fails to detect concomitant mono- and biallelic losses at 13q (Fabris et al, 
2011). However, the availability of multiple probes in MLPA allows the identification of 
genetic aberrations which are not incorporated in the standard FISH probe panel. In 
conclusion, MLPA can be used alone or in association with FISH to detect both recurrent 
and less frequent lesions in CLL. 
2.4 Comparative genomic hybridization and single nucleotide polymorphism arrays 
Very recently (2000s), comparative genomic hybridization arrays (aCGH) and single 
nucleotide polymorphism (SNP)-arrays have been validated as reliable tools to investigate 
global genetic abnormalities in CLL with a higher resolution (i.e. 200 basepairs – 10 
kilobases), compared with FISH and conventional cytogenetics. Therefore, it allows to 
detect new, cytogenetically cryptic, recurrent chromosomal changes, such as 
microdeletions. 
However, aCGH has shortcomings as it detects genomic imbalances, but not balanced 
aberrations. In contrast with aCGH, SNP-arrays have the additional advantage of detecting 
copy number neutral loss of heterozygosity (cnLOH) or uniparental disomy (UPD). LOH 
results from the loss of normal function of one allele of a gene in which the other allele has 
already been inactivated, whereas UPD is a cnLOH in which all copies of an allele are 
derived from one parent and no copies from the other parent are present. Until now, the 
application of aCGH and SNP-arrays is restricted to research setting, but may possibly be 
implemented in routine analysis of CLL in the near future. As many platforms from 
different companies are available and each platform has its own technical specifications, Fig 
5. gives only a brief and general overview of the technique. In the next paragraphs, we will 
focus in detail on the main results. 
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Fig. 5. Array-technology: summarized procedure.  
PB, peripheral blood; BM, bone marrow; BAC, bacterial artificial chromosome 
2.5 Next generation sequencing 
Next-generation sequencing (NGS, also known as massively parallel sequencing) 
technologies have a higher throughput than traditional sequencing methods. It allows 
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millions of sequencing reactions to happen in parallel, using different approaches, either by 
creating micro-reactors and/or attaching DNA molecules to solid surfaces or beads. Unlike 
previous methods NGS generates millions of short reads (21-400 base pairs) and does not 
require amplification as sequencing can be performed from a single DNA molecule. The 
short reads can be quantified, allowing accurate copy number assessment. Moreover, with 
approaches that sequence both ends of a DNA molecule (paired end massively parallel 
sequencing), it has become possible to detect balanced and unbalanced somatic 
rearrangements (i.e. fusion genes) in a genome-wide fashion. Since each type of NGS has 
specific artefacts, one should be aware of this phenomenon and new findings should be 
interpreted with caution (Reis-Filho, 2009). In addition, the high cost of the technique limits 
its use in (routine) practice. 
3. Cytogenetic and molecular abnormalities in CLL prognosis 
3.1 Five prognostically important FISH-categories 
A landmark interphase FISH-study of 325 mainly untreated CLL patients identified five 
prognostically important hierarchical categories: 17p deletion (with or without concomitant 
lesions), 11q deletion (with no concomitant 17p deletion), 12 trisomy (with neither 
concomitant 17p- nor 11q deletion), none of these aberrations, and 13q deletion as the sole 
abnormality (Fig 6. and Fig 7.). Median survival times for patients in these five groups were 
32, 79, 114, 111, and 133 months, respectively and the treatment-free survival was 9, 13, 33, 
49 and 92 months, respectively (Döhner et al, 2000).  
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Fig. 6. Idiogram of G-banded chromosomes involved in prognostically important 
aberrations, at 550-band level.  
Commonly deleted regions are indicated in red (caveat: deletions may be larger or smaller). 
Del(13q) type Ib can vary in length, as indicated by the dashed line. 
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Fig. 7. Examples of the four prognostically important aberrations in CLL, namely del(17p) 
(1), del(11q) (2), trisomy 12 (3) and del(13q) (4, 5), as observed by CCA (A), interphase FISH 
(B), metaphase FISH (C) and the Affymetrix 2.7M array platform (D). Applied FISH-probes 
are specific for TP53 (red) and centromere 17 (CEP17) (green) (1), for ATM (red) and 
centromere 12 (green) (2+3), for RB1 (green) and D13S319 (red) (4+5). Note a monoallelic 
loss of TP53 (B1, C1, D1 red arrow), monoallelic loss of ATM (B2, C2, D2 red arrow), trisomy 
12 (B3, C3, D3 blue arrow), a monoallelic (B4, C4, D4 cases A+B+C, single red arrows) and 
biallelic del(13q) in (B5, C5, D4 case C, double red arrow).  
3.1.1 17p deletions 
Patients with a deletion of 17p have worst outcome. The del(17p) is found in 3-8% of previously 
untreated patients, although higher incidences up to 45% have been reported in patients with 
relapsed or refractory CLL, as a consequence of clonal selection (Cramer and Hallek, 2011; Zenz 
et al, 2011). Del(17p) usually encompasses the TP53 locus at 17p13. A gene-dosage effect of TP53 
has been reported. About 80-90% of the cases harbor a biallelic inactivation of TP53 (i.e. deletion 
of one copy and mutation of the remaining copy), but also the monoallelic inactivation of TP53 
is an adverse prognostic marker (Cramer and Hallek, 2011; Zenz et al, 2011). The tumor 
suppressor p53 plays an essential role in inducing apoptosis or cell cycle arrest after DNA 
damage. Since therapy with purine nucleoside analogues (e.g. fludarabine) and alkylating 
agents (e.g. chlorambucil) is based on p53-dependent mechanisms, CLL patients with deletion 
17p or inactivating mutations of TP53 are refractory to such chemotherapy (Van Bockstaele et al, 
2008) and have impaired survival. A threshold of > 20-25% interphase nuclei harboring the 
del(17p) has been reported to correlate with adverse survival (Catovsky et al, 2007; Tam et al, 
2009). Because of the very poor prognosis, risk-adapted treatment for this subgroup has been 
developed. Current treatment approaches (in clinical trials) use agents acting independently of 
p53 (e.g. alemtuzumab, high dose steroids) or allogeneic stem cell transplantation for fit patients 
(Zenz et al, 2011). In the future, optimization of the therapeutic strategies hopefully may 
improve outcome for this poor prognostic subgroup. 
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3.1.2 11q deletions 
Deletions of 11q have been associated with adverse outcome. It is found in about 20% of the 
patients with CLL (Van Bockstaele et al, 2008; Zenz et al, 2011). The minimally deleted region 
(MDR) at 11q22.3-q23.1 harbors the ATM (ataxia telangiectasia mutated) gene. ATM is a 
protein that acts upstream of p53 in the DNA damage response pathway. Mutations of ATM 
have been reported in 12% of patients with CLL and in 30% of patients with del(11q) (Zenz 
et al, 2011). As not all patients with del(11q) have an ATM mutation (and vice versa), haplo-
insufficiency of ATM or the presence of other tumor suppressor genes in the MDR can be 
suspected. In the patients with del(11q), the biallelic inactivation of ATM leads to a worse 
clinical outcome (Cramer and Hallek, 2011). Of note, rarely the del(11q) does not encompass 
ATM, but affects the telomerically located FDX locus (Heim and Mitelman, 2009). Patients 
with del(11q) are generally younger, have more B-symptoms and more advanced clinical 
stages. Furthermore, the del(11q) is typically associated with extensive lymphadenopathy 
(Cramer and Hallek, 2011; Van Bockstaele et al, 2008). 
3.1.3 Trisomy 12 
An intermediate outcome has been described for patients with trisomy 12. While 
progression free survival (PFS) may be shorter (PFS rate at 3 years of 48-83%), overall 
survival (OS) is rather favorable (OS rates at 3 years of 86-96%). Trisomy 12 has been 
associated with atypical morphology or immunophenotype (i.e. stronger surface 
immunoglobulin and FMC7 expression) (Zenz et al, 2011). The aberration is observed in 10-
30% of patients (Van Bockstaele et al, 2008; Zenz et al, 2011). This variation probably reflects 
differences in patient selection. Partial trisomy 12q was reported in 10-20% of the cases and a 
minimal common gained region has been confined to 12q13 (Heim and Mitelman, 2009).  
The critical genes involved in the trisomy 12 are yet unknown. Small duplications of 12q have 
been reported and in particular the murine double minute 2 gene (MDM2) located at 12q15 has 
been found amplified in CLL (Merup et al, 1997). Overexpression of the MDM2 protein was also 
observed in CLL and this was significantly more frequent in the advanced rather than the 
earlier stages (Watanabe et al, 1996). The MDM2 SNP309 in B-CLL has been suggested to be an 
unfavorable prognostic marker; however the results of several recent publications are 
conflicting (Willander et al, 2010). The CLL upregulated gene 1 (CLLU1) located at 12q22 was 
overexpressed exclusively in CLL and its expression was shown to have a strong prognostic 
significance in patients younger than 70 years, namely higher expression was associated with 
shorter overall survival (Josefsson et al, 2007). However overexpression of CLLU1 occurs 
irrespectively of trisomy 12 or other large chromosomal rearrangements (Buhl et al, 2006). 
Recurrent association of trisomy 12 with IG-aberrations, such as t(14;19)(q32;q13), 
t(14;18)(q32;q21) and del(14)(q24q32), and with trisomy 18 and/or trisomy 19, has been 
observed in a subset of cases (Heim and Mitelman, 2009). Trisomy 12 with concomitant 
TP53 mutations is rare.  
3.1.4 13q deletions 
Although deletions of 13q are often cytogenetically cryptic, they represent the most frequently 
observed FISH-aberration in CLL, with a prevalence of 40-60% (Van Bockstaele et al, 2008). 
Only when present as a solitary aberration (by FISH), the del(13q) implies a favorable 
prognosis. Higher percentages (that is > 65% or > 80%) of interphase FISH nuclei showing the 
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del(13q) have been associated with shorter overall survival and time to first treatment 
(Hernandez et al, 2009; Van Dyke et al, 2010). The MDR located at 13q14 contains  miR-15a and  
miR-16-1. These microRNAs are small non-coding RNA genes that regulate gene expression. 
The miR-15a/16-1 cluster seems to negatively regulate the expression of multiple genes 
involved in proliferation and apoptosis (Klein and Dalla-Favera, 2010). Deletion of the MDR-
region in mice models suggested that this lesion is sufficient for lymphomagenesis. In some 
CLL cases without del(13q), downregulation of miR-15a and miR-16-1 has been described, 
suggesting an epigenetic mechanism suppressing the miR-cluster (Klein and Dalla-Favera, 
2010). Mutations in the miR-cluster appear to be very rare (Zenz et al, 2011). The del(13q) is 
most frequently heterozygous (monoallelic, 76% of cases), but can be homozygous (biallelic, 
24% of cases). While the former is suggested to be an early event, the latter probably occurs at 
a later stage. A gene dosage-effect of miR-15a/16-1 has been reported (Zenz et al, 2011). In 
addition, SNP-arrays showed that the extent of the deletion (Fig 6) is associated with disease 
characteristics, for example del(13q) type II (long, involving RB1, related with disease 
progression) and del(13q) type I (short, not involving RB1, related with disease progression 
only when associated with other aberrations) (Malek et al, 2010; Zenz et al, 2011).  
3.2 Other cytogenetic aberrations 
Several other recurrent genomic aberrations have been described in CLL, such as del(6q), 
del(14)(q24.1q32.33) involving IGH (Pospisilova et al, 2007), t(1;6)(p35;p25) involving 
MUM1/IRF4 (Michaux et al, 2005), total or partial trisomy 3, trisomy 8, trisomy 18 and 19 and 
changes leading to gains of 2p24-25, 3q26-27, and 8q24. These aberrations are rare in CLL 
(prevalence < 5-10%). Most of the genes involved are not yet identified and their prognostic 
relevance remains to be investigated (Heim and Mitelman, 2009; Van Bockstaele et al, 2008).  
3.3 Translocations 
Translocations have been reported in up to 34-42% of patients with CLL (Mayr et al, 2006; Van 
Den Neste et al, 2007). Balanced translocations are relatively rare, but unbalanced non-
reciprocal aberrations are frequent and are often observed within complex karyotypes. 
Although translocations are heterogenous in CLL, many breakpoints are located in regions 
showing recurrent loss, like 13q14 and 17p13 (Heim and Mitelman, 2009). Chromosomal 
translocations in general may have a negative impact on response to therapy and survival, 
especially when unbalanced (Mayr et al, 2006; Van Den Neste et al, 2007). Balanced 
translocations, especially those involving immunoglobulin (IG) genes, are recurrent, but 
uncommon (i.e. 5%) (Haferlach et al, 2007). Recurrent partners include BCL2, BCL3, BCL11A 
and MYC (Table 2). In published reports (Cavazzini et al, 2008; Nowakowski et al, 2007), at 
least part of the cases have unknown partner genes. In most studies, CLL cases with 
translocations involving IG are analyzed as a single group (Cavazzini et al, 2008; Juliusson et al, 
1990). However, the partner gene that becomes overexpressed as a result of the translocation, 
may be relevant for the outcome. The best described is the BCL3 gene involved in the t(14;19), 
often associated with atypical morphology, unmutated IGVH genes and inferior prognosis 
(Cavazzini et al, 2008; Chapiro et al, 2008; Martin-Subero et al, 2007; Nowakowski et al, 2007). 
Similarly, translocations involving MYC have been associated with loss (i.e. monosomy) of 17, 
del(11q) complex karyotype, additional unbalanced translocations and poor prognosis (Put et 
al, 2011). In contrast, translocations involving BCL2 are associated with mutated IGVH genes, 
trisomy 12, absence of del(11q) and more favorable outcome (Put et al, 2009b).  
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Translocationa,b 
Partner 
Gene 
Morphology IGVH Associated changes Prognosis 
t(2;14)(p16;q32) BCL11a Atypical U > M Trisomy 12 Uncertain 
t(8;14)(q24;q32) MYC PL /PT U ≈ M 
Monosomy  17p 
Del(11q) 
Complex karyotype 
Unbalanced translocations 
Poor 
t(14;18)(q32;q21) BCL2 Typical M > U 
Trisomy 12 
Absence of del(11q) 
Favorable 
t(14;19)(q32;q21) BCL3 Atypical U > M Trisomy 12 Poor 
PL, prolymphocyte; PT, prolymphocytic transformation; U, unmutated; M, mutated 
aIG-translocations involve most frequently IGH located on 14q32. Variant translocations involve either 
IGK on 2p12 or IGL on 22q11 
b To date, most cases with t(11;14)(q13;q32), involving CCND1, are diagnosed as mantle cell lymphoma; 
however, rare cases of t(11;14)-positive CLL might exist. 
Table 1. Overview of translocations involving immunoglobulin (IG)-genes in CLL 
3.4 Genomic complexity 
Cytogenetic complexity is defined as the presence of three or more clonal chromosomal 
aberrations. CCA was found to be superior in the detection of complexity, compared with 
FISH (Haferlach et al, 2007), probably due to the limited number of investigated loci in the 
latter approach. Complexity is found in a minority of the cases with CLL (10-30%) (Haferlach 
et al, 2007; Kujawski et al, 2008). A highly significant association was observed between 
complex aberrant karyotypes and 17p deletions, unmutated IGVH and expression of CD38 
(Haferlach et al, 2007). In addition, particular aberrations (i.e. translocations involving MYC) 
have also been associated  with a complex aberrant karyotype (Put et al, unpublished data). 
Prognostically, patients with complex genomic changes appear to have more aggressive 
disease. Similarly, genomic complexity detected by SNP-arrays (≥ 3 genetic lesions) has been 
associated with poor outcome (Kujawski et al, 2008). An impaired apoptotic DNA double-
strand break response and multiple genomic deletions, including del(17p), del(11q), and 
del(13q) type II were identified as independent strong predictors of genomic complexity in 
CLL. Moreover, a strong independent effect of aberrant p53 function on genomic complexity 
and a modest effect of decreased ATM function have been observed (Ouillette et al, 2010). Such 
multiple independent gene defects in CLL may contribute to genomic instability. In addition, 
telomere dysfunction as a consequence of telomere erosion may also drive genomic instability 
during the progression of CLL (Lin et al, 2010). Indeed, short telomeres have been associated 
with a high risk of genomic aberrations and genetic complexity (Roos et al, 2008).  
3.5 Clonal evolution 
Clonal evolution (CE) represents the acquisition of new or additional cytogenetic aberrations 
during disease course. As a consequence, CCA or FISH should not only be used for initial 
prognostication of patients with CLL, but also at the time of disease progression or before 
therapy initiation [FISH is mandatory in this setting for detection of del(17p)]. Initially, CE as 
evaluated by sequential CCA, was considered infrequent, i.e. in 16% of CLL patients (Oscier et 
al, 1991). Later studies reported higher frequencies of 25-43% (Fegan et al, 1995; Finn et al, 1998; 
Haferlach et al, 2007). Interphase FISH studies (Table 2) revealed CE in 27% and 17% after a 
median follow-up of more than 5 years and 42.3 months, respectively (Shanafelt et al, 2006; 
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Stilgenbauer et al, 2007). Interestingly, CE occurred more frequently among cases with 
unmutated IGVH status (Shanafelt et al, 2006; Stilgenbauer et al, 2007). However, another study 
did not find a correlation between CE and unmutated IGVH, expression of CD38 and ZAP70 
on one hand, but the combination of all three prognostic factors correlated highly significantly 
with CE and with a shift from lower to higher FISH risk category (Berkova et al, 2009). Patients 
with CE showed progression to more advanced stages, greater need for therapy and a higher 
hazard ratio for death. Moreover, CE was identified as an independent factor for survival 
(Stilgenbauer et al, 2007). As a consequence, CCA or FISH should not only be used for initial 
prognostication of patients with CLL, but also at the time of disease progression or before 
therapy initiation [FISH is mandatory in this setting for detection of del(17p)] 
Reference 
CLL 
Patients 
(n) 
Follow-
up 
(months) 
CE: 
patients 
(n) 
CE: 
previously 
treated 
patients (n) 
CE: abnormalities Other findings 
Shanafelt  
et al, 2006 
108a 
67 (23-
136) 
18 (11%) 13 (71%) 
del(13q) (72%) > 
del(17p) (22%) > 
del(11q) (6%) 
CE not confined to unmutated IGVH 
(association ns) 
Correlation between ZAP70+ and CE 
CE more frequent after 50 months 
compared with before 24 months 
(27% vs. <2%, respectively) 
Stilgenbauer 
et al, 2007 
64 
42 (23-
73) 
11 (17%) 1 (9%) 
del(17p) (36%) > 
del(13q) = del(6q) (27%) 
> del(11q) (18%) > +8q24 
(9%) 
CE confined to unmutated IGVH 
CE correlates with progressive clinical 
stages, greater need for therapy, 
higher hazard ratio for death 
CE as independent factor for survival 
Berkova  
et al, 2009 
97 
66 (22-
304) 
25 (26%) 7 (28%) 
del(13q) (64%) > 
del(17p) = del(11q) 
(16%) > trisomy 12 (4%) 
Combination of unmutated IGVH, 
CD38+ and ZAP70+ correlates highly 
significantly with CE and with a shift 
from lower to higher FISH risk 
category 
Loscertales  
et al, 2010 
81 
67 (16-
111) 
17 (21%) 13 (76%) 
del(17p) (53%) > 
del(11q) (35%) 
CE not confined to unmutated IGVH 
del(17p) observed in untreated 
patients 
N, number; CE, clonal evolution; ns, not significant,  
aSequential samples were available in 108/159 patients. 
Table 2. Overview of clonal evolution investigated by FISH 
3.6 Molecular karyotyping 
The introduction of aCGH and SNP-arrays enables to investigate CLL at a resolution, greatly 
surpassing this of conventional cytogenetics. Different array-platforms were validated as a 
powerful, cost-effective tool for clinical risk assessment in CLL (Table 3) (Gunn et al, 2008; 
Hagenkord et al, 2010; O'Malley et al, 2011). Of note, the sensitivity of these platforms varies 
and is related to i.e. the resolution of the array. For example, the Affymetrix SNP6.0 array was 
found to be superior to the 250K array in detecting small aberrations of uncertain significance 
and equivalent to the 250K array in detecting clinically relevant lesions. Since the cost of the 
250K array is lower, it is preferred for routine use. In contrast, the 10K array is not suitable for 
routine clinical use due to its low resolution (Hagenkord et al, 2010).  
New recurrent cytogenetic abnormalities were detected by aCGH and SNP-arrays. In Table 3 
an overview of selected publications on array-applications in CLL is shown, describing known 
prognostically important lesions and new molecular cytogenetic findings (Grubor et al, 2009; 
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Gunn et al, 2008; Gunn et al, 2009; Gunnarsson et al, 2008; Gunnarsson et al, 2010; Gunnarsson 
et al, 2011; Hagenkord et al, 2010; Kay et al, 2010; Kujawski et al, 2008; Lehmann et al, 2008; 
O'Malley et al, 2011; Ouillette et al, 2010; Ouillette et al, 2011; Pfeifer et al, 2007; Rinaldi et al, 
2011). Other recent studies using array-platforms revealed new insights in the disease: i.e. the 
genome of CLL appeared to be quite stable over time (Brown et al, 2010); disease progression 
has been associated with large, but not small copy number alterations (Gunnarsson et al, 2010), 
genomic complexity, 13q deletion in the presence of other aberrations, and 13q deletion type II 
(that is, deletions involving RB1) (Malek et al, 2010). 
 
Table 3. Overview of selected publications on genomic array-applications in CLL 
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Table 3 (continued).  
17, Del(17p); 11, Del(11q); 12, Trisomy 12; 13, Del(13q); NA, not available; LOH, loss of 
heterozygosity; CN, copy number neutral; UPD, uniparental disomy; UM, unmutated; M, 
mutated; IGVH, immunoglobulin heavy chain mutational status; CGH, comparative 
genomic hybridization; TTT, time to treatment; CNA, copy number alteration;  
PFS, progression-free survival; CE, clonal evolution; 
aUntreated – treated patients, respectively;  
bSolitary del(13q) only;  
cAt diagnosis + at follow-up, respectively;  
dLowest frequency of (partial) gain of 12q 
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3.7 Next generation sequencing 
Whole genome sequencing of cases with CLL led to the discovery of several genes, 
previously unsuspected to be involved in this disease. For example, combining NGS and 
copy number analysis in 5 patients, < 20 clonal genomic alterations/case and recurrent 
mutations of NOTCH1, TGM7, BIRC3, and PLEKHG5 were observed (Fabbri et al, 2011). 
Lesions of MYD88, BIRC3, and PLEKHG5 are all linked to alteration of the NF-κǃ pathway. 
In a screening cohort of 48 CLL cases, NOTCH1 mutations were found in 8.3% of CLL cases 
at diagnosis and were associated with aggressive disease (i.e. higher frequency of NOTCH1 
mutations were associated with Richter transformation and refractoriness to chemotherapy, 
in 31.0% and 20.8% of the cases, respectively). Moreover NOTCH1 mutation at diagnosis 
emerged as an independent risk factor for poor survival (Fabbri et al, 2011). Another NGS 
and exome sequencing study identified four genes that were recurrently mutated, namely 
NOTCH1, XPO1 predominantly in CLL with unmutated IGVH, and MYD88 and KLHL6 in 
CLL with mutated IGVH status (Puente et al, 2011). NOTCH1, XPO1 and MYD88 mutations 
are suspected to be oncogenic changes, contributing to disease progression, based on their 
patterns of mutation and functional analyses, (Puente et al, 2011). In conclusion, NGS 
appears to be a highly effective technique in identifying new genetic lesions and future 
studies are promising to contribute to an improved understanding of disease onset and 
evolution. 
4. The origin of cytogenetic abnormalities  
Genomic imbalances, such as gains and losses of chromosome segments or whole 
chromosomes (aneuploidy), are more frequently observed than translocations in CLL. 
However, in the following paragraphs we will focus mainly on the origin of translocations, 
in particular translocations involving IG loci, as the underlying mechanisms are quite 
specific for lymphoid malignancies, i.e. CLL. 
4.1 The origin of aneuploidy and structural aberrations 
Aneuploidy may arise due to defects in segregation of chromosomes during cell division, 
including multipolar spindles, but also abnormal kinetochore-spindle interactions, premature 
chromatid separation, centrosome amplification, and abnormal cytokinesis. Defects of 
centrosome function in particular have been suggested to be involved in a wide variety of 
human malignancies. Centrosomes have central role in organizing microtubuli and the mitotic 
spindle. An aberrant number, size, shape of the centrosome, as well as aberrant 
phosphorylation of centrosome proteins, may missegregate chromosomes, resulting in 
aneuploid cells. In addition, errors in the separation of sister chromatids could also be a cause 
of aneuploidy. Finally, checkpoint controls are expected to be abrogated in order to enable 
unequal chromosome segregation during cell cycle progression (Gollin, 2004; Schwab, 2001). 
Structural chromosomal instability results from chromosome breakage and rearrangement 
due to defects in the cell cycle checkpoints, the DNA damage response and/or loss of 
telomere integrity (Gollin, 2004). When a chromatid break occurs, an unprotected 
chromosomal end will probably fuse with either another broken chromatid or its sister 
chromatid to produce a dicentric chromosome. During the anaphase, the two centromeres 
www.intechopen.com
 Chronic Lymphocytic Leukemia 
 
288 
are pulled to opposite poles, forming a bridge that breaks, resulting in more unprotected 
chromosomal ends, thus resulting in breakage-fusion-bridge cycles. Telomere mechanics, 
defects in DNA damage response and cell cycle checkpoint may play important roles in the 
development and maintenance of chromosomal instability (Gollin, 2004). 
4.2 The origin of translocations 
Recurrent translocations in CLL often involve IG loci. These translocations may follow DNA 
double strand breaks (DSBs) that are generated during V(D)J recombination (i.e. 
recombination of Variable, Diversity, and Joining segments of IG-genes) and somatic 
hypermutation (SHM) in developing B-cells and in the context of class switch recombination 
(CSR) in activated mature B-cells. DSBs in the partner loci may be generated by off-target 
VDJ recombination, CSR activities or may result from more general factors, such as 
oxidative metabolism or genotoxic agents. Misrepair of these DSBs can promote oncogenic 
translocations. When a translocation involves oncogenes or tumor suppressor genes, it can 
be positively selected in the context of neoplastic transformation. Selection likely plays the 
main role in the appearance of most clonal translocations in tumors (Gostissa et al, 2011).  
4.2.1 VDJ recombination and RAG-mediated DSB 
The complete VDJ recombination involves RAG-mediated cleavage, which generates DSBs, 
and the DSB repair pathway “classical nonhomologous DNA end-joining” (C-NHEJ). The 
latter promotes chromosomal integrity and suppresses the formation of translocations. In 
the absence of C-NHEJ, DSBs still can be joined by alternative end-joining (A-EJ), a process 
that contributes to oncogenic chromosomal translocations (Gostissa et al, 2011; Nussenzweig 
and Nussenzweig, 2010). 
4.2.2 SHM, CSR and AID-mediated DSB 
Although representing different processes, SHM and CSR are both initiated by AID 
(Gostissa et al, 2011; Perez-Duran et al, 2007). SHM generates point mutations, small 
deletions and insertions in variable region exons. This occurs in the germinal centers (GCs) 
and allows the selection of B-cells that express higher affinity B-cell receptors. CSR can also 
occur within the GC, as well as in extrafollicular regions (Gostissa et al, 2011). 
AID initiates both SHM and CSR in B-cells by deaminating cytosines on the DNA of IG 
genes. The generated lesion can be processed into a mutation (SHM) or a DSB followed by a 
recombination reaction (CSR) (Perez-Duran et al, 2007). CSR requires the generation of AID-
initiated DSBs. In contrast, SHM generally does not require DSBs. The latter are only 
occasionally generated as by-products of AID activity (Gostissa et al, 2011). It has been 
suggested that AID may have a dual role; initiating chromosomal translocations on one 
hand and generating secondary hits by mutagenesis on the other (Perez-Duran et al, 2007). 
Aberrant SHM and involvement of AID were reported to be involved in mutations of TP53 
(Malcikova et al, 2008), MYC, PAX5 and RhoH (Reiniger et al, 2006). Moreover, AID activity 
has been linked to the generation of DSBs involved in translocations in both IG and non-IG 
loci (Gostissa et al, 2011). While AID was shown to initiate the formation of translocations 
and mutations, ATM, p53 and ARF provide surveillance mechanisms to prevent these 
aberrations (Perez-Duran et al, 2007). 
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AID expression results from interaction with an activated microenvironment. In a study of 
CLL patients with unmutated IGVH, high AID expression was found exclusively in the 
small subset of cells with ongoing CSR (Palacios et al, 2010). In addition, in CLL and small 
lymphocytic lymphoma, AID expression has been associated with unfavorable clinical 
course and with adverse biological parameters, i.e. higher proliferation rate, deletion of 
ATM and TP53 (Leuenberger et al, 2010). AID expression has been considered to be 
predictive for CLL with unmutated IGVH status (Palacios et al, 2010). However, in other 
reports the association of AID expression and IGVH mutational status is considered 
controversial (Leuenberger et al, 2010).  
4.2.3 Combined action of RAG and AID 
In conclusion, RAG and AID can generate DSBs leading to translocations via VDJ 
recombination and CSR, respectively. RAG and AID are usually expressed in distinct B-cell 
developmental compartments. Activity of RAG has been observed in developing bone 
marrow B-cells, whereas AID activity has been found in peripheral mature B-cells. 
Breakpoint sequences can provide information regarding the developmental stage at which 
the translocation occurred (Gostissa et al, 2011; Nussenzweig and Nussenzweig, 2010). 
However, collaboration between RAG and AID in generating translocations has been 
reported. RAG induced DSBs can persist in the absence of ATM, an essential DNA damage 
checkpoint regulator, or in absence of the NHEJ factor XRCC4, leading to abnormal or 
delayed repair of RAG-mediated DSBs. In addition, AID may facilitate off-target DSB 
formation by RAG. As a consequence RAG and AID-mediated DSBs may coexist and 
become partners in translocation formation (Nussenzweig and Nussenzweig, 2010). Finally, 
not all DSBs that are precursors of translocations in lymphomas appear to be initiated by 
RAG or AID (Gostissa et al, 2011). The mechanism(s) involved herein remain largely 
unknown. 
4.2.4 Oncogene activation 
Most recurrent translocations activate oncogenes, either by generating oncogenic fusion 
proteins or by deregulating oncogene expression by linking it to strong transcriptional 
control elements. The IGH locus contains two known major transcriptional enhancer 
regions: the intronic enhancer (iEμ), which promotes optimal VDJ recombination in 
developing B-cells and the IGH 3′ regulatory region (IGH3′RR), which modulates CSR in 
mature B-cells by long-range (over 100 kb) activation of certain promoters. The IgH3′RR 
does not gain full enhancer activity until late in B-cell development. It was reported that 
iEµ has low oncogenic activity, suggesting that VDJ-mediated translocations that retain 
iEμ near the translocation breakpoint may arise in early B-cell developmental stages but 
remain oncogenically silent until the IgH3′RR becomes fully active at the mature B-cell 
stage. Alternatively, the development of mature B-cell tumors from cells carrying VDJ-
mediated translocations might reflect the time required for the accumulation of 
secondary mutations necessary for transformation. Another explanation is that 
translocations may be generated directly in mature B-cells, either by persisting VDJ 
breaks arisen at the pro-B-cell stage or by RAG-mediated breaks in peripheral B-cells 
(Gostissa et al, 2011). 
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survival rates ranging from months to decades. It is clear that clinical heterogeneity reflects biologic diversity
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CLL progresses, abnormal hematopoiesis results in pancitopenia and decreased immunoglobulin production,
followed by nonspecific symptoms such as fatigue or malaise. A cure is usually not possible, and delayed
treatment (until symptoms develop) is aimed at lengthening life and decreasing symptoms. Researchers are
playing a lead role in investigating CLL's cause and the role of genetics in the pathogenesis of this disorder.
Research programs are dedicated towards understanding the basic mechanisms underlying CLL with the hope
of improving treatment options.
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